HC Wainwright Decreases Earnings Estimates for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO) – HC Wainwright dropped their Q4 2027 earnings per share (EPS) estimates for shares of AngioDynamics in a note issued to investors on Wednesday, July 15th. HC Wainwright analyst Y. Chen now expects that the medical instruments supplier will post earnings per share of $0.01 for the quarter, down from their prior forecast of $0.05. HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.27) per share.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. The company had revenue of $86.61 million during the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

Several other research firms have also commented on ANGO. Zacks Research lowered AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Canaccord Genuity Group boosted their price target on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $19.50.

AngioDynamics Stock Down 4.5%

ANGO opened at $13.51 on Thursday. The company has a market cap of $558.37 million, a PE ratio of -15.53 and a beta of 0.34. AngioDynamics has a twelve month low of $8.36 and a twelve month high of $15.19. The company has a 50-day moving average price of $12.24 and a 200 day moving average price of $11.35.

Institutional Trading of AngioDynamics

Hedge funds have recently made changes to their positions in the company. Farther Finance Advisors LLC raised its position in shares of AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 1,199 shares during the period. Kemnay Advisory Services Inc. purchased a new position in AngioDynamics in the fourth quarter worth approximately $27,000. State of Wyoming purchased a new position in AngioDynamics in the second quarter worth approximately $31,000. Russell Investments Group Ltd. increased its stake in AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 3,213 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 4,268 shares during the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Trending Headlines about AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on AngioDynamics and maintained a $19 price target, signaling confidence in the company’s longer-term upside despite ongoing losses. MarketBeat ANGO
• Positive Sentiment: An earlier report said AngioDynamics set a new 52-week high following an analyst upgrade, which likely reinforced bullish sentiment around the name. AngioDynamics Sets New 52-Week High Following Analyst Upgrade
• Neutral Sentiment: HC Wainwright cut several fiscal 2027 EPS estimates for AngioDynamics, including Q1, Q2, Q4, and full-year forecasts, reflecting a more cautious near-term earnings outlook. MarketBeat ANGO
• Neutral Sentiment: Despite the lower estimates, HC Wainwright still projects AngioDynamics will narrow losses over time, with FY2027 EPS estimated at ($0.27), close to the broader consensus of ($0.26). MarketBeat ANGO
• Negative Sentiment: A Seeking Alpha piece titled “AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)” suggests some analysts see limited upside after the recent run, which could temper enthusiasm. Seeking Alpha article

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.